Taken together, the data showed that the two methodological approaches, expression of FRNK and siRNA against FAK, inhibited FAK-mediated signalling pathways in HNSCC-derived cells, and were suitable tools to address the question as to whether FAK is involved in HNSCC progression. The gene discussed is PTK2; the disease is head and neck squamous cell carcinoma.